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Abstract: The CpG island methylator phenotype (CIMP), together with extensive promoter 
methylation, is regarded as one of the mechanisms involved in colorectal carcinogenesis 
(CRC).  The mechanisms underlying the presence of CIMP in sporadic colorectal cancer are 
poorly understood. Genes involved in methyl-group metabolism are  likely to affect DNA 
methylation and thereby influence an individual's susceptibility to CIMP. To test this 
hypothesis, we examined the potential association between the polymorphisms of MTHFR 
677C>T, TS 5’UTR 2R/3RG>C, TS 3’UTR 1494del6, MTHFD1 401G>A, DNMT3B -149C>T 
and DNMT3B -283T>C and the presence of CIMP in a group of 186 sporadic CRC cases and 
100 controls. The CIMP status of the tumors was determined by a panel of five markers 
(CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1), which was also followed by analysing 
hMLH1 methylation and BRAF V600E mutation. Individuals with TS 3R/3R had an increased 
risk of CIMP- colorectal cancer (OR = 2.38, 95% CI = 1.0-5.7; P = 0.042, Fisher's exact test) 
when compared with 2R/2R homozygotes. Individuals with DNMT3B -283 CC  reduced risk 
of CIMP+ colorectal cancer (OR = 0.220, 95% CI = 0.0226-1.07; P = 0.046, Fisher's exact 
test)  when compared to -283 TT carriers. This study provides some support to the hypothesis 
that methyl-group metabolism plays a role in the etiology of both CIMP+ and CIMP - 
colorectal cancers. 
 
 
 
 
  
Introduction:  
Epigenetic inactivation linked to CpG island hypermethylation andassociated silencing have 
been regarded as a common hallmark of human cancer. Recently, great advances have been 
made in understanding epigenetic alterations in colorectal cancer. Leading to the discovery of 
the CpG island methylator phenotype (CIMP). CIMP defines a subset of colorectal tumors  
that exhibit an exceptionally high frequency of methylation of a number of CpG islands. 
CIMP colorectal tumors also display other specific features including proximal location, high 
BRAF V600E and low TP53 mutation rates and finally a high degree of microsatellite 
instability (MSI-H)  associated  with hMLH1 promoter hypermethylation. Although CIMP is 
presently being increasingly studied, the primary cause for the defect in the methylation 
machinery leading to CIMP still remains unknown. However, the body of evidence that has 
accumulated over the past decade suggests that altered folate and methionine status can 
influence DNA methylation and is related to the risk of sporadic colorectal cancer. Given that 
folate in the form of 5-methyltetrahyrofolate is responsible for remethylation of the  precursor 
of the S-adenosylhomocysteine (SAM), which is a donor of methyl groups for DNA 
methylation, it may be hypothesized that polymorphisms of the genes involved in methyl-
group metabolism are likely to be associated with CIMP. A number of single nucleotide 
polymorphisms (SNPs) have been described  in the context of colorectal cancer for several 
genes involved in methyl group metabolism. Among these candidate genes, we focused on 
sequence variants in the methylenetetrahydrofolate reductase (MTHFD1), thymidylate 
synthase (TS), methylenetetrahydrofolate redutase (MTHFR) and DNA methyltranferase 
(DNMT3B). MTHFD1 is a trifunctional folate enzyme that plays a role in nucleotide synthesis 
(of purines). The MTHFD1 401G>A SNP changes an arginine to a lysine in the 
dehydrogenase/cyclohydrolase domain of MTHFD1 and is thought to affect these activities. 
Although no studies have investigated the functional consequences of this SNP, two reports 
have shown its association with a significant increase in the risk of colorectal and breast 
cancer. TS also plays an essential role in nucleotide synthesis (thymidylate) by converting  
5,10 – methyletetetrhydrofolate to dihydrofolate. Two common polymorphisms that can alter 
TS mRNA transcription have been described. Both are located .in the TS untranslated regions 
(UTRs). One of them is a 28bp tandem repeat in TS 5’UTR that contains two or three repeats 
(2R/3R). The triple repeat has been shown to enhance TS mRNA and protein expression in 
vitro and in vivo possibly because 3R alleles contain C>G SNP that alters the activation of TS 
transcription. The second TS polymorphism is a 6bp deletion located in 3’UTR (1494del6) 
and has been associated with decreased TS mRNA stability in vitro. Both TS SNPs have been 
studied in relation with several cancers. However, only TS 2R/3R has been found to be 
associated with susceptibility to colorectal cancer.  MTHFR competes with TS for 5,10 – 
methylenetetrahydrofolate and catalyses it to 5- methyltertahydrofolate that serves as a methyl 
donor for SAM. The MTHFR 677C>T SNP which reduces the availability of methionine for 
DNA methylation via a reduction of 40% - 70% in the level of enzyme activity belongs to the 
most frequently studied SNPs within the group of folate-metabolising genes and has been 
found to be associated with susceptibility to several cancers including colorectal cancer.  
Finally, DNA methyltransferases (DNMTs) catalyze the transfer of a methyl group from SAM 
to a cytosine ring, usually located within the context of a CpG dinucleotide in DNA. Although 
three DNMTs have been identified in humans, only two functional SNPs have been found in 
one of the DNMTs to date. DNMT3B -149C>T and -283T>C SNPs are located in the 
promoter region of the DNMT3B gene. In the in vitro promoter assays, both SNPs revealed a 
significant change in the transcriptional activity of the DNMT3B promoter (an increase of 
30% in activity for the -149T allele and a decrease of 50% for the -283T allele). Both SNPs 
have been found to be associated with an  increased risk of lung cancer.  It can be speculated 
that these SNPs may increase the risk of cancer via increasingly aberrant de novo methylation 
of CpG islands and thus transcriptional repression of some tumor suppressor genes. 
So far many studies have investigated possible associations between  variants in methyl-group 
metabolizing genes and colorectal cancer, whereas little investigation has been focused on 
their relations with CIMP. Interestingly, a very recent paper by Curtin et al. provided some 
evidence for a folate-related CIMP etiology. They studied the relationship between CIMP and 
the  genetic variation ??? in one carbon metabolism in a large cohort of sporadic colorectal 
cancers. Although their research provided only a few weak associations specific to CIMP, the 
authors indicated a possible correlation of the methylenetetrahydrofolate reductase (MTHFR) 
1298A>C polymorphism, together with low folate and high alcohol intake, with CIMP.  
Given the importance of folate metabolism in DNA methylation, we  hypothesize that in 
addition to variants involved in metabolising folates ???, SNPs in genes  directly responsible 
for DNA methylation might be a further modulating factor on CIMP colorectal cancer 
.Therefore, the aim of this study was to investigate whether MTHFR 677C>T, TS 5’UTR 
2R/3RG>C, TS 3’UTR 1494del6, MTHFD1 401G>A, DNMT3B -149C>T and DNMT3B -
283T>C variants are associated with CIMP colorectal tumors. 
Materials and methods: 
Sample of Patients  and Tissue Samples: 
This study included 186 cancer cases and 100 healthy controls. The control group and cases 
consisted entirely of Polish individuals (all Caucasians), who came from the same geographic 
area. Surgically resected frozen tissues of colorectal cancers and matched blood samples were 
obtained from the 2nd Department of General and Oncological Surgery and Department of 
Pathophysiology, Wroclaw Medical University. The tumors analyzed represent a cohort of 
186 sporadic CRC. Only patients with primary colorectal cancer who had not received 
preoperative therapy were included. Healthy controls were obtained from……No individual 
in the control group had previous had a tumor of any type or a family history of 
gastrointestinal neoplasms. The study was accepted by the Wroclaw Medical University 
Ethics Committee. Genomic DNA was prepared using standard phenol-chloroform extraction 
and ethanol precipitation. 
 
BRAF V600E mutation 
Detection of BRAF V600E was carried out using a standard procedure. Briefly, mutant allele-
specific PCR was used to amplify the exon 15 regionof the BRAF gene. Reactions to detect 
the presence of a wild-type or mutant allele were performed in a PTC 200 DNA Engine 
Thermal cycler (MJ Research, Inc. Waltham, MA). PCR products with an expected size of 
125 bp were resolved on a 2.5% agarose-ethidium bromide gel. Because mutant allele–
specific PCR amplification carries the risk of false-positive/false-negative results, special 
precautions were taken and all samples were reexamined for the BRAF V600E mutation 
twice. 
 
Bisulfite Treatment of DNA, Methylation-Specific PCR and CIMP 
 
Bisulfite treatment of genomic DNA obtained from resected frozen tissues was carried out 
using a standard procedure. Approximately 50 ng of the modified DNA was amplified in a 
PTC 200 DNA Engine Thermal cycler (MJ Research, Inc. Waltham, MA) with primers 
specific to either the methylated or unmethylated promoter sequences of the CACNA1G, 
IGF2, NEUROG1, RUNX3, SOCS1 and hMLH1 genes. The primer sequences and 
amplification conditions of methylation-specific PCR utilized in this study are described 
elswere (citations ??. CIMP was defined by the use of  aspecific panel of markers and citeria 
described by Weiseberger et al. Briefly, after the analysis of the methylation of a panel of 5 
markers (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1), CIMP+ tumors were defined 
as those with  at least 3 methylated CIMP markers. CIMP- tumors were defined as those with 
at most 2 methylated CpG islands. 
Genotyping 
The genotyping of  MTHFR 677C>T, TS 5’UTR 2R/3RG>C, TS 3’UTR 1494del6, MTHFD1 
401G>A, DNMT3B -149C>T and DNMT3B -283T>C was performed according to standard 
PCR-RFLP methods. All PCR reactions were done separately in a 10µl  reaction volume 
containing 1x PCR buffer (Qiagen), 1.5 mmol/L MgCl2, 200 µmol/L deoxynucleoside 
triphosphate, 40 ng of genomic DNA, 0.2 µmol/L of each primer, and 0.75 units of Taq DNA 
polymerase (Qiagen). All PCR reactions were set with an initial denaturation of 5 min at 95°C 
and subsequently denatured for 30s at 95°C, with annealing for 30s at the appropriate 
temperature for each primer and extension for 30s at 72°C. Thirty-five cycles were used to 
amplify the PCR products to the expected product sizes in a PTC 200 DNA Engine Thermal 
cycler (MJ Research, Inc., Waltham, MA). The PCR reactions were digested  overnight using 
appropriate restriction enzymes (Frementas, Takara, NEB). The primer sequences and 
appropriate amplification temperatures are shown in Table 1.  For the detection of the THFD1 
401G>A polymorphism, DNA was amplified with the F 5'GATGTGGATGGGTAAGTG3' 
and R  5'TACAAGGAATGAAACAGT3' primers. The 220bp PCR product was digested by 
the BsmAI restriction enzyme (NEB) and analyzed on a 2.5% agarose-ethidium bromide gel. 
The expected fragments were of length 131bp,  49bp and 40bp for the G allele and 180bp and 
40bp for the A allele, whereas the band pattern for the GA heterozygote yielded 180bp, 
131bp,  49bp and  40bp bands. 
 
Statistical methods 
............................. 
 
 
Results 
The characteristics of study group, both overall and with respect to CIMP status, are shown in 
Table 2. The mean age of controls (75±7 years) was significantly higher than that of the CRC 
patients (65±10). The distribution of gender differed between the cases and the controls. 
Female subjects were overrepresented in control group. 
About 25% (n=47) of all CRC patients displayed CIMP (at least 3 of 5 markers methylated) 
and 75% (n=139) of all CRC cases  were classified as CIMP- (from 0 to 2 markers 
methylated). A strongly bimodal distribution of tumors according to the number of methylated 
loci was observed (data not shown). The BRAF V600E mutation was found in 23 (12.4%) of 
186 CRCs, including 6 (4,3%) of the 139 CIMP- tumors and 17 (36.2%) of the 47 CIMP+ 
tumors. A similar pattern was observed for the frequency of hMLH1 methylation, which was 
present in 19 (10.2%) of all CRC cases, including 4 (2.9%) of the CIMP- tumors and 15 
(32%) of the CIMP+ tumors. The BRAF V600E mutation and  hMLH1 methylation  were 
significantly associated with CIMP [OR = 12.33, 95% CI = 4.21-41.54; p = 1.8×10-7 and OR 
= 15.5, 95% CI = 4.54-68.65; P = 2.8× 10-7, respectively, Fisher's exact test]. 
We genotyped the study participants for six polymorphisms in  methyl-group metabolizing 
genes (MTHFR 677C>T, TS 5’UTR 2R/3RG>C, TS 3’UTR 1494del6, MTHFD1 401G>A, 
DNMT3B -149C>T and DNMT3B -283T>C). The distribution of the genotypes  and analysis 
of CRC cases and controls are provided in Table 2.  Among the cases and controls all 
genotypes were distributed in accordance with the Hardy-Weinberg equilibrium. The  
DNMT3B -149C>T and DNMT3B -283T>C were in strong LD in the cases and controls (for 
the control group estimates ofD'  = 0.7148 r
2
 = 0.5218 P = 5.1×10-13). Pairwise analysis 
indicated no significant increase in risk of CRC for any combination of DNMT3B genotypes  
(data not shown).   Analysis also revealed a lack of significant associations between the 
investigated SNPs and CRC. However, there was a suggestion of a correlation between the TS 
3R/3R genotype and CRC  (P = 0.058, Mantel-Haenszel Test). As shown in Table 3, 
comparison of CIMP+ and CIMP- revealed a borderline negative association between  the 
DNMT3B -283 CC genotype and CIMP+ CRCs (OR = 0.22, 95% CI = 0.022-1.07; p=0.050, 
here comparison is made with the TT genotype, the most frequency homozygote, and Fisher’s 
exact test was used). Results from comparingCIMP+ cases with the control group (Table 4) 
showed that the presence of the TS 3R/3R genotype resulted in ~2-fold increased risk of 
CIMP- CRC compared with the 2R/2R genotype (OR = 2.38, 95% CI = 1.01-5.70; P = 0.046, 
Fisher’s exact test). There was also an indication of positive association between the MTHFR  
667 CT genotype and CIMP- CRC. However, this did not attain statistical significance 
(comparing with the most frequent homozygote, CC, OR = 1.73, 95% CI = 0.97-3.10; P = 
0.054). When CIMP+ cases were compared with controls (Table 4), a negative association 
between the DNMT3B -283 CC genotype and CIMP+ CRC could be observed (comparing 
with TT, OR = 0.22, 95% CI = 0.023-1.07; P = 0.046). 
 
Discussion 
Polymorphisms in methyl-group metabolizing genes have drawn considerable interest 
recently because of evidence of their influence on global DNA methylation in the cell and 
therefore possible modulation of CIMP. 
In the present case-control study we investigated associations between polymorphisms in 
methyl-group metabolizing genes and sporadic CRC cases with respect to their CIMP status.  
.Most of the analyzed polymorphisms did not show any significant difference in the genotype 
distribution between CIMP-/CIMP+ cases and controls which may be due to the modest 
sample size and thus lack of statistical power, particularly for CIMP+ CRCs. However, a few 
possible associations emerged from our data. 
We found that carriers of the TS 3R/3R genotype have an increased risk of CIMP – CRC. 
Irrespective of CIMP status, similar associations for CRC have been reported in other case-
control studies. In a  study of 270 sporadic CRCs and 454 control subjects, Chen et al. 
reported a higher risk of CRC for 3R3R carriers than for 2R2R homozygotes. In a subsequent 
study Chen et al. found that the 3R3R genotype significantly increases the risk of colorectal 
adenoma among individuals with high alcohol consumption. Finally, Urlich et al. reported a 
significantly increased  risk of colorectal polyps among TS 3R3R individuals with low and 
medium folate consumption. The TS 2R/3R locus is a tandem repeat polymorphism consisting 
of either two or three 28bp repeats and is located near the initiation site of the TS promoter. 
The 3R allele has been related to enhanced TS expression with the greatest effect observed in 
the presence of the 3R3R genotype. Given that TS catalyze reactions in DNA synthesis, 
affecting the methyl-donor supply for DNA methylation, it can be hypothesized that the 
increased TS expression associated with the 3R3R genotype may lead to a decrease in global 
DNA methylation of the cell. The notion that global DNA demethylation increases 
chromosomal instability, which is characteristic of CIMP- CRCs, supports our hypothesis of 
an association between the TS 3R3R genotype and CIMP- CRCs. In agreement with other 
published results, we did not find any evidence that the TS 3’UTR 1494del6 polymorphism 
and combined TS genotype were associated with either the risk of CRC or CIMP+ CRC. 
We also found a lower risk of CIMP+ CRC for DNMT3B -283 CC individuals compared to -
283 TT individuals. DNMT3B mediates de novo DNA methylation, with the –283 T allele 
postulated to decrease in vitro promoter activity by 50% compared with the –283 C allele. In 
an initial study by Lee et al. the carriers of the -283 T allele had a significantly decreased risk 
of lung cancer in a Korean population.  The negative association of the DNMT3B -283 CC 
genotype and CIMP+ is therefore contrary to our expectations. Although in our case-control 
comparison the DNMT3B -283 T>C polymorphism was in strong LD with the DNMT3B -
149C>T nucleotide substitution, there was no evidence of an association of the DNMT3B -
149C>T polymorphism  either with CIMP+ or CIMP- tumors. However, it is possible that our 
results reflect a different level of linkage disequilibrium than in the Korean population, 
possibly with another unidentified, functional polymorphism that modulates DNA methylation 
via DNMT3B.  
Very little data are available on CIMP and polymorphisms involved in methyl-group 
metabolism. Our data, although there are negative results for most of the polymorphisms 
studied, is mostly convergent with an interesting paper by Curtin et al., which also reported a 
few associations with CIMP. However, the methods used to classify CIMP differ substantially 
between these articles, which is likely toaffect the outcomes. In this study we used the 
classification procedure and marker panel proposed by Weisenberger et al., a strongly 
bimodal distribution of the number of methylated loci was observable in our CRC group. The 
appropriateness of our CIMP classification was additionally confirmed by a highly significant 
association of the BRAF V600E mutation and hMLH1 methylation with CIMP, which has 
recently also been demonstrated by other groups.  
Although our study suffers from having a limited sample size and lack of diet history, as data 
accumulate on the modifying effect of methyl-group metabolism on CIMP+ and CIMP-  
CRCs, the application of such results may prove useful.  
In conclusion, our results show that polymorphisms involved in methyl-group metabolism 
may play some role in the etiology of CIMP+ and CIMP- colorectal cancer. As CIMP+ and 
CIMP- CRC tumors differ in regard to their molecular background, it is likely that 
polymorphisms involved in methyl-group metabolism will have different effects in such 
distinct subgroups of colorectal cancer. 
  
 
 
 
 
 
 
Table 1. Primer sequences and annealing temperatures used for polymorphisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP primers (5’→3’) annealing 
temperature 
(°C) 
reference 
MTHFR 677C>T F  
TGAAGGAGAAGGTGTCTGCGGGA 
R  AGGACGGTGCGGTGAGAGTG 
69  
TS 5’UTR 2R/3R F  AGGCGCGCGGAAGGGGTCCT 
R  TCCGAGCCGGCCACAGGCAT 
69  
TS 3’UTR 1494del6 F  CAAATCTGAGGGAGCTGAGT 
R  CAGATAAGTGGCAGTACAGA 
66  
DNMT3B -149C>T F  TGCTGTGACAGGCAGAGCAG 
R  GGTAGCCGGGAACTCCACGG 
69  
 DNMT3B -283T>C F  GAAAAAGGCCCCAGAAGGC 
R  GGCGGGGACGAGGGAAATTT 
66  
MTHFD1 401G>A F  GATGTGGATGGGTAAGTG 
R  TACAAGGAATGAAACAGT 
59  
  
Table 2 Characteristics of the study  and control groups 
    Controls   Cases   OR 95% C. I. Fisher Ordinal  
    N % N  %   p-value p-value 
All subjects   100   186         
Men   30 30 105 56.5       
Women   70 70 81 43.5 
  2.2×10-
5   
Age   74.89 [7.63] 65.51 [10.53] 
  3.4×10-
13   
MTHFR C667T                 
CC   50 50 74 39.8 *** ***     
CT   40 40 97 52.2 1.64 [0.95,2.83]     
TT   10 10 15 8.1 1.01 [0.39,2.74] 0.14 0.2 
MTHFD R134K                 
CC   65 65 132 71 *** ***     
CT   33 33 49 26.3 0.73 [0.42,1.29]     
TT   2 2 5 2.7 1.23 [0.19,13.25] 0.49 0.34 
DNMT3B 
T283C           
  
    
CC   18 18 23 12.4 0.75 [0.34,1.66]     
CT   43 43 96 51.6 1.30 [0.73,2.29]     
TT   39 39 67 36 *** *** 0.27 0.88 
DNMT3B 
C149T           
  
    
CC   38 38 56 30.1 *** ***     
CT   44 44 91 48.9 1.40 [0.78,2.51]     
TT   18 18 39 21 1.47 [0.70,3.15] 0.41 0.21 
TS 2R/3R                 
2R/2R   23 23 36 19.4 *** ***     
2R/3R   59 59 94 50.5 1.02 [0.52,1.96]     
3R/3R   18 18 56 30.1 1.98 [0.88,4.49] 0.08 0.058 
TS 2R/3R G/C                 
2R/2R   23 23 36 19.4 *** ***     
2R/3C   35 35 68 36.6 1.24 [0.60,2.53]     
2R/3G   21 21 27 14.5 0.82 [0.35,1.91]     
3C/3C   12 12 27 14.5 1.43 [0.56,3.75]     
3G/3C   8 8 22 11.8 1.75 [0.62,5.33]     
3G/3G   1 1 6 3.2 3.77 [0.42,183.7] 0.51 * 
TS 1494del                 
del/del   5 5 11 5.9 0.53 [0.15,1.93]     
ins/del   41 41 90 48.4 1.39 [0.82, 2.38]     
ins/ins   54 54 85 45.7 *** *** 0.43 0.2 
5UTR/3UTR                 
High/High   7 7 8 4.3 0.53 [0.15,1.93]     
High/Low   22 22 46 24.7 0.97 [0.46,2.06]     
Low/High   46 46 78 41.9 0.79 [0.41,1.48]     
Low/Low   25 25 54 29 *** *** 0.63 * 
MLH1                 
positive       19 10.2       
negative       167 89.8       
BRAF                 
positive       23 12.4       
negative       163 87.6       
 
Fisher p-value refers to Fisher’s exact test for independence.  
Ordinal p-value refers to the Mantel-Haenszel test for independence using the number of  
non-wild type alleles as an explanatory variable. 
 
 
 
  
Table 3. Association between polymorphisms in methyl-group metabolism genes and CIMP status in tumors, case-case comparioson 
  Cimp -ve  
Cimp 
+ve   OR 95% C.I. Fisher Ordinal 
  N  % N %         
All subjects 139 74.7 47 25.3         
Men 76 54.7 29 61.7         
Women 63 45.3 18 38.3     0.5 0.79 
Age 64.63 [10.26] 68.11 [11.00]     0.042 0.05 
MTHFRC677T                 
CC 54 38.8 20 42.6 *** ***     
CT 75 54 22 46.8 0.79 [0.37,1.70]     
TT 10 7.2 5 10.6 1.35 [0.32,5.00] 0.58 0.86 
MTHFDR134KCT                 
CC 96 69.1 36 76.6 *** ***     
CT 39 28.1 10 21.3 0.69 [0.28,1.58]     
TT 4 2.9 1 2.1 0.67 [0.01,7.06] 0.74 0.74 
DNMT3B283TC                 
TT 47 33.8 20 42.6 *** ***     
CT 71 51.1 25 53.2 0.83 [0.39,1.77]     
CC 21 15.1 2 4.3 0.22 [0.02,1.07] 0.12 0.13 
DNMT3B149CT                 
CC 43 30.9 13 27.7 *** ***     
CT 64 46 27 57.4 1.39 [0.61,3.29]     
TT 32 23 7 14.9 0.73 [0.22,2.23] 0.34 0.79 
TS 2R3R                 
3R3R 24 17.3 12 25.5 *** ***     
2R3R 70 50.4 24 51.1 1.4 [0.59,3.49]     
2R2R 45 32.4 11 23.4 2.03 [0.70,5.94] 0.32 0.11 
TS2R3RGC                 
2R/3C 24 17.3 12 25.5 *** ***     
2R/2R 54 38.8 14 29.8 1.92 [0.70,5.25]     
2R/3G 17 12.2 10 21.3 2.25 [0.75,6.66]     
3C/3C 23 16.5 4 8.5 0.67 [0.15,2.46]     
3G/3C 17 12.2 5 10.6 1.13 [0.28,3.99]     
3G/3G 4 2.9 2 4.3 1.91 [0.16,14.97] 0.3 * 
TS1494del6                 
ins/ins 8 5.8 3 6.4 *** ***     
ins/del 67 48.2 23 48.9 1.05 [0.50,2.20]     
del/del 64 46 21 44.7 1.14 [0.18,5.34] 1 0.82 
5UTR/3UTR                 
Low/High 5 3.6 3 6.4 *** ***     
Low/Low 32 23 14 29.8 0.95 [0.38,2.35]     
High/Low 60 43.2 18 38.3 1.45 [0.59,3.56]     
High/High 42 30.2 12 25.5 1.98 [0.28,11.38] 0.58 * 
MLH1                 
neg 4 2.9 15 31.9 *** ***     
pos 135 97.1 32 68.1 15.5 [4.54,68.65] 2.8×10-7 2.8×10-7 
BRAFV600E                 
neg 6 4.3 17 36.2 *** ***     
pos 133 95.7 30 63.8 12.33 [4.21,41.54] 1.8×10-7 1.8×10-7 
 
 
 
 
 
 
  
Table 4. Association between polymorphisms in methyl-group metabolism genes and CIMP status in tumors, case-control comparison 
MTHFRC677T Control CIMP +ve OR 95% CI 
Fisher's 
exact 
Mantel-
Haenszel CIMP -ve OR 95% CI Fisher's Exact Mantel-Haenszel 
CC 50 20 *** *** ***   54 *** *** ***   
CT 40 22 1.3716 [0.6181,3.0625] 0.456   75 1.7317 [0.9731,3.1001] 0.0544   
TT 10 5 1.2466 [0.2960,4.6446] 0.759   10 0.9265 [0.3162,2.7139] 1   
As a whole         0.712 0.476       0.102 0.209 
                        
MTHFDR134K                       
CC 65 36 *** *** ***   96 *** *** ***   
CT 33 10 0.5493 [0.2156,1.3074] 0.174   39 0.801 [0.4404,1.4599] 0.474   
TT 2 1 0.9036 [0.0149,17.9110] 1   4 1.3518 [0.1875,15.3596] 1   
As a whole         0.303 0.180       0.687 0.559 
                        
DNMT3B283                       
TT 39 20 *** *** ***   47 *** *** ***   
CT 43 25 1.1326 [0.5134,2.5174] 0.853   71 1.3679 [0.7451,2.5159] 0.311   
CC 18 2 0.2201 [0.0226,1.0727] 0.046   21 0.9683 [0.4236,2.2258] 1   
As a whole         0.064 0.227       0.467 0.735 
                        
DNMT3B149                       
CC 38 13 *** *** ***  43 *** *** ***   
CT 44 27 1.79 [0.76, 4.33] 0.174  64 1.2837 [0.6895,2.3938] 0.459   
TT 18 7 1.13 [0.32, 3.72] 1.000  32 1.5656 [0.7192,3.4735] 0.276   
As a whole      0.312 0.485       0.461 0.209 
                   
TS 2R/3R                  
2R/2R 23 12 *** *** ***   24 *** *** ***   
2R/3R 59 24 0.7814 [0.3121,2.0113] 0.662   70 1.1362 [0.5506,2.3425] 0.735   
3R/3R 18 11 1.1684 [0.3706,3.6788] 0.799   45 2.3761 [1.0097,5.7013] 0.046   
As a whole         0.600 0.884       0.042 0.021 
                        
TS 2R/3R G/C                  
2R/2R 23 12 *** *** ***   24 *** *** ***   
2R/3C 35 14 0.7691 [0.2732,2.1779] 0.636   54 1.4742 [0.6807,3.2023] 0.362   
2R/3G 21 10 0.9140 [0.2868,2.8699] 1   17 0.7781 [0.3012,1.9913] 0.664   
3C/3C 12 4 0.6444 [0.1241,2.7751] 0.746   23 1.8232 [0.6824,5.0302] 0.259   
3G/3C 8 5 1.1934 [0.2493,5.2944] 1   17 2.0165 [0.6658,6.5244] 0.215   
3G/3G 1 2 3.6913 [0.1756,235.375] 0.542   4 3.7467 [0.3372,196.6240] 0.358   
As a whole         0.762 ***       0.252 *** 
                        
TS1494del6                       
ins/ins 54 21 *** *** ***  64 *** *** ***   
ins/del 41 23 1.44 [0.66, 3.15] 0.362  67 1.3768 [0.7837,2.4299] 0.281   
del/del 5 3 1.53 [0.22, 8.72] 0.685  8 1.347 [0.3634,5.5547] 0.771   
As a whole         0.592 0.296       0.478 0.245 
                      
5UTR/3UTR                       
Low/Low 25 12 *** *** ***   42 *** *** ***   
Low/High 46 18 0.8169 [0.3122,2.1802] 0.658   60 0.7775 [0.3939,1.5186] 0.526   
High/Low 22 14 1.3206 [0.4562,3.8746] 0.630   32 0.8668 [0.3898,1.9290] 0.712   
High/High 7 3 0.8950 [0.1270,4.8514] 1   5 0.43 [0.0965,1.7668] 0.21   
As a whole         0.735 ***       0.565 *** 
 
 
 
    
 
  
